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Abstract
Background: Preliminary studies have shown the potential use of salivary creatinine concentration in the diagnosis
of chronic kidney disease (CKD). For saliva to replace serum as a diagnostic tool, studies must be done to
determine its effectiveness in the diagnosis and staging of CKD. The aim of the present study was to evaluate the
use of salivary creatinine as a safe and non-invasive alternative for identifying patients with CKD.
Methods: A cross-sectional study was conducted at Tygerberg Hospital in Cape Town, on 230 patients, across all
stages of CKD. Ethical approval to conduct the study was obtained from the University of the Western Cape
Biomedical Research Ethics Committee, and written informed consent was provided by each participant. Saliva and
serum samples were collected for creatinine analysis and the correlation determined using Spearman’s correlation.
Receiver operating characteristics (ROC) analysis was used to determine the diagnostic ability of salivary creatinine.
A cut-off value for optimal sensitivity and specificity of salivary creatinine to diagnose CKD with glomerular filtration
rate (GFR) < 60 mL/min/1.73 m2 was obtained.
Results: Serum creatinine values ranged from 46 μmol/L to 1581 μmol/L, with a median value of 134 μmol/L.
Salivary creatinine values ranged from 3 μmol/L to 400 μmol/L, with a median of 11 μmol/L. There was a strong
positive correlation (r = 0.82) between serum and salivary creatinine values. Linear regression analysis of serum and
salivary creatinine for CKD patients was significant in all CKD stages, except for stage 1. Area under the curve for
salivary creatinine was 0.839. A cut-off value of 8.5 μmol/L yielded a sensitivity of 78.3% and specificity of 74.0% for
classifying patients as having CKD based on estimated GFR < 60 mL/min/1.73 m2.
Conclusions: The results support the potential of salivary creatinine as a non-invasive diagnostic tool for estimating
GFR and identifying patients with CKD.
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Background
Chronic kidney disease (CKD) is an important public
health problem with an estimated global prevalence of
11 to 13% [1, 2]. The major drivers of this epidemic are
the increases in new cases of diabetes mellitus and
hypertension. CKD may lead to kidney failure and is also
a strong risk factor for heart disease and stroke. In
addition, there is a large impact on quality of life [3].
A systematic review of the burden of CKD in the gen-
eral population and high-risk groups in Africa reported
prevalences ranging from 2 to 41% [4]. A review of the
burden of CKD in sub-Saharan Africa by Stanifer et al.
estimated the population prevalence of CKD at 13.9%
[5]. In South Africa, two population prevalence studies
have been published. Matsha et al. reported a crude
prevalence of 17.3% in a geographical cohort [6], while
Adeniyi et al. reported an age-adjusted prevalence of
6.4% in a cohort of teachers [7].
The assessment of glomerular filtration rate (GFR) is
an important part of the diagnosis and staging of CKD.
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Markers used to measure GFR include inulin, creatinine,
urea and cystatin C. Creatinine is the most commonly
used marker in clinical practice [8]. GFR is estimated from
measurements of creatinine concentrations in blood, using
various prediction equations. In adults, the Chronic Kid-
ney Disease Epidemiology Collaboration (CKD-EPI) and
the Modification of Diet in Renal Disease (MDRD)
study equations are the most widely used [3]. A simple
diagnostic test that does not require a blood sample and
provides a reliable evaluation of CKD status would be of
benefit to both patients and healthcare providers.
Saliva contains various components that may be used as
biomarkers to detect systemic diseases or exposure to
harmful substances. Salivary research is growing rapidly [9],
due to the application of new scientific approaches such as
bioinformatics, metabolomics, genomics and proteomics.
Saliva has been shown to be useful in detecting various
local diseases such as oral, head and neck cancers [10],
lung, pancreatic, breast and ovarian cancers [11–14] and in
the diagnosis of systemic diseases such as type 2 diabetes.
Recent studies have investigated the role of saliva as a
substitute for serum or plasma in the diagnosis of CKD.
These studies have mainly focused on its use in end-
stage renal disease (ESRD) [15–17]. For saliva to replace
blood as a diagnostic and monitoring tool for CKD,
more studies must be conducted to demonstrate its ef-
fectiveness in diagnosing CKD and to classify patients
into the correct CKD stage. Our study therefore investi-
gated the correlation between serum and salivary cre-
atinine levels to evaluate the role of saliva as a safe and
non-invasive alternative for GFR estimation to identify
patients with CKD.
Methods
This cross-sectional study was conducted between February
and May 2017 at the outpatient clinics of the Division of
Nephrology at Tygerberg Hospital, a large public sector fa-
cility in Cape Town, South Africa. Patients 18 years and
older who were willing to provide informed consent, were
considered for inclusion in the study. Patients were excluded
if they had any oral condition causing bleeding into the oral
cavity.
CKD diagnosis and staging
A GFR < 60mL/min/1.73m2 is used as an important cut-
off for the diagnosis of CKD. This level defines stage 3
CKD. Stage 4 CKD is defined by GFR < 30mL/min/1.73
m2 and stage 5 by GFR < 15mL/min/1.73m2. Stages 1
(GFR ≥ 90mL/min/1.73m2) and 2 (GFR 60–89mL/min/
1.73m2) are diagnosed only when there are other markers
of kidney damage present (e.g. proteinuria, imaging abnor-
malities, functional or histological abnormalities) [3].
Sample size
The sample size was calculated using the estimated means
of salivary creatinine in known test and control groups
[18], with the level of significance set at 0.05 and the
power at 90%. The calculated minimum sample size for
each stage of CKD was rounded up to 40 participants,
which provided for an attrition rate of 20%. CKD staging
was based on participants’ estimated GFR (eGFR). Those
with evidence of kidney disease for more than 3months
with GFR greater or equal to 90mL/min/1.73m2 were
classified into stage 1; GFR between 60 and 89mL/min/
1.73 m2 were classified into stage 2; GFR between 30 and
59mL/min/1.73m2 was classified into stage 3; GFR be-
tween 15 and 29mL/min/1.73m2 was classified into stage
4 and those with GFR less than 15mL/min/1.73m2 were
classified into stage 5. Patients on dialysis were excluded
from the study.
Table 1 The frequency distribution of patients by CKD stages, gender, age and comorbidities
Gender Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Total
Male 16 17 23 19 14 89
(38.7%)
Female 34 33 27 21 26 141
(61.3%)
All 50 50 50 40 40 230
(100%)
Age range Median age
Interquartile range (Q1-Q3)
18–54
31.0
(21.25-39.75)
19–73
38.5
(31.25-49.50)
19–73
38.0
(31.0-51.0)
20–82
40.5
(33.75-47.5)
21–66
47.5
(40.5-54.25)
Patients with co-morbidities 34 47 44 39 40 204
Hypertension and
diabetes (2)
Hypertension and
diabetes (7)
Hypertension and
diabetes (5)
Hypertension and
diabetes (4)
Hypertension and
diabetes (10)
Hypertension (28) Hypertension (36) Hypertension (34) Hypertension (32) Hypertension (29)
Diabetes (1) Diabetes (2) Diabetes (2) Diabetes (1) Diabetes (0)
Other (3) Other (2) Other (3) Other (2) Other (1)
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Saliva and blood sampling
Saliva collection was carried out between 09:00 am and 12:
30 to minimize the effect of diurnal variation. Participants
were instructed to refrain from eating and drinking at least
90min before collection and to thoroughly rinse their
mouths with water, prior to the sample collection, to void
the mouth of saliva. Two mL of whole saliva was collected
in a sterile graduated container by the spitting method. Par-
ticipants were asked to sit in a comfortable position with
eyes open and head tilted slightly forward and to avoid
swallowing or other oral movements during collection. The
pooled saliva in the floor of the mouth was spat into the
container every 60 s or just before they experienced an urge
to swallow the accumulated fluid. This process was re-
peated until 2mL of whole saliva was obtained.
Immediately after saliva sample collection, 2mL of blood
was collected from patients’ antecubital veins in serum sep-
arator tubes. Blood samples were allowed to clot at room
temperature for one hour and then centrifuged at 1000 g
for 10min at 4 °C. The saliva samples were centrifuged at
1000 g at for 10min and the supernatant obtained was
stored at − 80 °C prior to final analysis. Creatinine levels in
saliva and serum were analyzed on a Roche cobas® 6000
analyzer, which uses an enzymatic method for creatinine
analysis.
Statistical analysis
Data were entered into MS Excel and analyzed using SPSS
v17.0. Spearman’s correlation coefficient (r) was used to
test the correlation between serum and salivary creatinine
levels. Linear regression equations were derived to esti-
mate the level of serum creatinine from the salivary levels.
Receiver operating characteristic (ROC) analysis was used
to evaluate the diagnostic potential of salivary creatinine
compared to serum creatinine. The overall performance
was assessed by the total area under the curve and the
cut-off values were determined based on the best trade-off
between the sensitivity and specificity.
Ethics approval and consent to participate
Approval to conduct the study was obtained from the
Biomedical Research Ethics Committee of the University
of the Western Cape (project number BM/16/5/4). All
participants provided written informed consent.
Results
The number of participants included in stages 1, 2 and 3
was increased to 50 each as these stages were the most
prevalent. Stages 4 and 5 included 40 participants each
and the final study cohort therefore comprised a total of
230 patients. There were more female participants over-
all (61.3%) and within each CKD group (Table 1).
The ranges of serum and salivary creatinine values
were 46–1581 μmol/L and 3–400 μmol/L, respectively.
Table 2 shows the ranges and medians for CKD stages 1
to 5, and for all patients combined. There was a strong
positive correlation (r = 0.82) between serum and salivary
creatinine when considering all samples, and a moderate
correlation for patients in CKD stages 2 to 5 (Table 3).
Linear regression analysis demonstrated an ability to
predict the serum creatinine from salivary creatinine in
CKD stages 2 to 5 (Fig. 1 and Table 4).
ROC analysis (Fig. 2) found the total area under the
curve to be 0.89 (standard error = 0.028, p-value < 0.001,
95% confidence interval = 0.784–0.894). Table 5 shows
the sensitivity and specificity for different values of
salivary creatinine; 8.50 μmol/L was determined as the
best cut-off value to diagnose CKD based on a GFR
value < 60 mL/min/1.73 m2. This cut-off point yielded a
sensitivity of 78.3% (false negative rate 21.7%), a specifi-
city of 74.0% (false positive rate 26%) and a positive pre-
dictive value (PPV) of 79.6%.
Discussion
The present study reported a progressive increase in sal-
ivary creatinine levels from CKD stages 1–5, consistent
with the findings of other studies [15–17], and a strong
overall correlation between serum and salivary creatinine.
Lloyd et al. reported a similar pattern in patients with CKD
stages 4 and 5 [19]. Linear regression also demonstrated a
significant relationship between serum and salivary creatin-
ine in CKD stages 2 to 5, with stage 5 having the highest
coefficient of determination. This is in line with previous
studies in which a significant predictive relationship was
found between serum and salivary creatinine in CKD stages
4 and 5. For CKD stage 1, the relationship between serum
and salivary creatinine was not significant; this is also
Table 3 Spearman correlation analysis of serum and salivary
creatinine
All patients Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
R 0.82 0.16 0.31 0.38 0.42 0.55
P < 0.001 0.250 0.030 0.005 0.007 < 0.001
Correlation is considered strong at (r = 1.0 to 0.5), moderate at (r = 0.3 to 0.5),
weak at (r = 0.1 to 0.3), very weak or no correlation at (r < 0.1)
Table 2 Serum and salivary creatinine (in μmol/L) for patients in CKD stages 1–5
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 All
Serum creatinine: (median) range 46–93 (66) 65–133 (91) 102–232 (149) 161–462 (276) 312–1581 (518) 46–1581 (134)
Salivary creatinine: (median) range 3–19 (6) 3–18 (9) 4–63 (16) 5–222 (29) 72–40 (68) 3–400 (11)
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consistent with results of previous studies [16, 17] and is
thought to be due to the lower serum creatinine levels, with
minimal movement of creatinine to saliva due to the lack of
a large concentration gradient.
Salivary creatinine can only be accepted as an alternative
diagnostic method if it is comparable to serum creatinine
in its ability to differentiate between those with and with-
out CKD [20]. ROC analysis showed a large area under
the curve for salivary creatinine, suggesting that it may be
a good alternative diagnostic test to identify CKD patients
with GFR below the critical value of 60mL/min/1.73m2.
Comparable large areas under the curve were reported in
Fig. 2 ROC curve of serum and salivary creatinine levels
Fig. 1 Linear regression between serum and salivary creatinine levels of all CKD patients
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previous studies. Xia et al. [21] obtained an area under
curve value of 0.897, while Ventakapathy et al. [17] ob-
tained a value of 0.967.
In the present study, the optimal cut-off point for the
diagnosis of CKD was determined to be a salivary creatinine
concentration of 8.5 μmol/L, which provided good sensitiv-
ity and specificity, and a high positive predictive value
(PPV) in our cohort of participants. This suggests that saliv-
ary creatinine could be used as a non-invasive tool in diag-
nosing CKD and that people with values above 8.5 μmol/L
should be referred for further diagnostic evaluation and ap-
propriate management. A study by Renda et al. [22] re-
ported a cut-off value of 0.125mg/dl (11.1 μmol/L) as the
optimum salivary concentration for diagnosis of CKD
among children in stage 2–5. Ventakapathy et al. [17] stud-
ied patients with stage 4 and 5, and reported a cut-off value
of 0.2mg/dl (17.7 μmol/L). The higher cut-off value re-
ported by Ventakapathy et al. may be due to the consider-
ation of only CKD stages 4 and 5, compared to the present
study which considered patients in stages 1–5. Correlation
studies of serum and salivary creatinine in healthy individ-
uals have reported conflicting results. Bader et al. [15]
found a positive correlation between serum and salivary
creatinine in patients without kidney disease, while other
studies have reported negative correlations [16, 17]. These
differences may be due to the presence of factors such as
diabetes mellitus, hypertension and salivary gland diseases,
which can influence the diffusion of creatinine from serum
into the salivary glands [23, 24]. Another potential con-
founder is medication use, which may alter salivary gland
cell permeability and thereby salivary creatinine concentra-
tions [25]. Other markers which have been used to estimate
renal function include salivary urea, which was first used in
the early part of the twentieth century [26]. Its concentra-
tion is more affected by non-renal factors than is the case
with creatinine [27]. These factors include hydration status,
protein intake, protein catabolism, liver diseases, gastro-
intestinal bleeding, and therapy with high-dose steroids
[27]. In view of these limitations, and because serum cre-
atinine is commonly used to estimate GFR, we focused on
this marker in the present study. It may be that a combin-
ation of several salivary markers may improve the accuracy
of assessing renal function and this needs to be tested in fu-
ture studies.
Limitations of this study include the use of estimated
GFR for evaluating renal function, rather than measured
GFR as determined by the clearance of iohexol or other
exogenous markers. Only a single salivary sample was
taken from each patient and we had an absence of healthy
controls. Considering that the sample was drawn from a
nephrology clinic, the proportion of subjects with CKD is
much higher than would be expected in a CKD screening
study of the general population. Additional studies are
needed to test the utility of salivary creatinine in these set-
tings where most of the subjects would be expected to
have normal or near-normal concentrations of serum cre-
atinine. Future studies should investigate whether salivary
creatinine is correlated with other clinical and laboratory
parameters, and should examine the utility of newer
markers of kidney damage, such as NGAL,
Conclusion
The present study has contributed to the existing data
supporting the diagnostic potential of salivary creatinine
as a non-invasive tool to estimate GFR. Salivary creatin-
ine concentrations above 8.5 μmol/L may identify pa-
tients with CKD and should prompt referral for further
diagnostic evaluation.
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Stage 1 0.465 Y = 64.9 + (0.23) × (salivary Cr) 0.008 0.80% 0.894
Stage 2 0.030 Y = 89.7 + (0.54) × (salivary Cr) 0.035 3.50% 0.187
Stage 3 0.008 Y = 134 + (0.95) × (salivary Cr) 0.140 14.0% 0.374
Stage 4 0.007 Y = 251 + (0.6) × (salivary Cr) 0.179 17.9% 0.423
Stage 5 0.001 Y = 451 + (1.72) × (salivary Cr) 0.275 27.5% 0.524
Table 5 Sensitivity and specificity analysis of salivary creatinine
for different cut-off values to diagnose CKD on the basis of
GFR < 60 mL/min/1.73 m2
Salivary creatinine (μmol/L) Sensitivity (%) Specificity (%)
3.5 99.4 26.0
4.5 97.2 26.0
6.5 86.1 56.0
8.5 78.3 74.0
11.5 64.4 88.0
14.5 60.6 90.0
15.5 57.8 92.0
Temilola et al. BMC Nephrology          (2019) 20:387 Page 5 of 6
Availability of data and materials
The datasets generated during the current study are available from the
corresponding author on request.
Ethics approval and consent to participate
Approval to conduct the study was obtained from the Biomedical Research
Ethics Committee of the University of the Western Cape (project number
BM/16/5/4). All participants provided written informed consent.
Consent for publication
Written informed consent was obtained to publish the study findings.
Competing interests
The authors declare that they have no competing interests.
Author details
1Division of Oral Medicine and Periodontics, Faculty of Dentistry, University
of the Western Cape, Cape Town, South Africa. 2Division of Nephrology,
Department of Medicine, Stellenbosch University and Tygerberg Hospital,
Cape Town, South Africa. 3Division of Chemical Pathology, National Health
Laboratory Service, Stellenbosch University and Tygerberg Hospital, Cape
Town, South Africa.
Received: 15 February 2019 Accepted: 29 August 2019
References
1. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of
chronic renal diseases. Lancet. 2001;357:1601–8.
2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FR.
Global prevalence of chronic kidney disease–a systematic review and meta-
analysis. PloS One. 2016;11(7):e0158765.
3. Eknoyan G, Lameire N. KDIGO 2012 clinical practice guideline for the
evaluation and management of chronic kidney disease. Kidney Int Suppl.
2013;3:1–150.
4. ElHafeez SA, Bolignano D, D’Arrigo G, Dounousi E, Tripepi G, Zoccali C.
Prevalence and burden of chronic kidney disease among the general
population and high-risk groups in Africa: a systematic review. BMJ Open.
2018;8(1):e015069.
5. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, et al. The
epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic
review and meta-analysis. Lancet Glob Health. 2014;2(3):e174–81.
6. Matsha TE, Yako YY, Rensburg MA, Hassan MS, Kengne AP, Erasmus RT.
Chronic kidney diseases in mixed ancestry south African populations:
prevalence, determinants and concordance between kidney function
estimators. BMC Nephrol. 2013;14(1):75.
7. Adeniyi AB, Laurence CE, Volmink JA, Davids MR. Prevalence of chronic
kidney disease and association with cardiovascular risk factors among
teachers in Cape Town, South Africa. Clin Kidney J. 2017;10(3):363–9.
8. Feher JJ. Quantitative human physiology: an introduction. Amsterdam:
Academic Press; 2012.
9. Ahmadi Motamayel F, Davoodi P, Dalband M, Hendi SS. Saliva as a mirror of
the body health. DJH. 2010;2:1–5.
10. John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and
interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous
cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(8):929–35.
11. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, et al. Systemic disease-
induced salivary biomarker profiles in mouse models of melanoma and
non-small cell lung cancer. PLoS One. 2009;4(6):e5875.
12. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, et al. Proteomic
identification of salivary biomarkers of type-2 diabetes. J Proteome Res.
2009;8(1):239–45.
13. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary
transcriptomic biomarkers for detection of resectable pancreatic cancer.
Gastroenterology. 2010;138(3):949–57.
14. Lee YH, Kim JH, Zhou H, Kim BW, Wong DT. Salivary transcriptomic
biomarkers for detection of ovarian cancer: for serous papillary
adenocarcinoma. J Mol Med. 2012;90(4):427–34.
15. Bader RS, Kora MA, El-Shalakany AH, Mashal BS. Clinical significance of saliva
urea and creatinine levels in patients with chronic kidney disease. Menoufia
Med J. 2015;28(2):406.
16. Lasisi TJ, Raji YR, Salako BL. Salivary creatinine and urea analysis in patients with
chronic kidney disease: a case control study. BMC Nephrol. 2016;17(1):10.
17. Venkatapathy R, Govindarajan V, Oza N, Parameswaran S, Pennagaram
Dhanasekaran B, Prashad KV. Salivary creatinine estimation as an alternative to
serum creatinine in chronic kidney disease patients. Int J Nephrol. 2014;2014.
https://doi.org/10.1155/2014/742724.
18. Tomás I, Marinho JS, Limeres J, Santos MJ, Araújo L, Diz P. Changes in salivary
composition in patients with renal failure. Arch Oral Biol. 2008;53(6):528–32.
19. Lloyd JE, Broughton A, Selby C. Salivary creatinine assays as a potential
screen for renal disease. Ann Clin Biochem. 1996;33(5):428–31.
20. Brown Connolly NE. A better way to evaluate remote monitoring programs
in chronic disease care: receiver operating characteristic analysis.
Telemedicine e-Health. 2014;20(12):1143–9.
21. Xia Y, Peng C, Zhou Z, Cheng P, Sun L, Peng Y, et al. Clinical significance of
saliva urea, creatinine, and uric acid levels in patients with chronic kidney
disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012;37(11):1171–6.
22. Renda R. Can salivary creatinine and urea levels be used to diagnose
chronic kidney disease in children as accurately as serum creatinine and
urea levels? A case–control study. Ren Fail. 2017;39(1):452–7.
23. Ladgotra A, Verma P, Raj SS. Estimation of salivary and serum biomarkers in
diabetic and non diabetic patients-a comparative study. J Clin Diagn Res.
2016;10(6):ZC56–61.
24. Briet M, Collin C, Karras A, Laurent S, Bozec E, Jacquot C, et al. Arterial remodeling
associates with CKD progression. J Am Soc Nephrol. 2011;22(5):967–74.
25. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in
cardiovascular disease enterprises: part I: aging arteries: a “set up” for
vascular disease. Circulation. 2003;107(1):139–46.
26. Hench PS, Aldrich M. A salivary index to renal function. JAMA. 1923;81(24):
1997–2003.
27. Edelstein CL. Biomarkers in acute kidney injury. Adv Chronic Kidney Dis.
2008;15(3):222–34.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Temilola et al. BMC Nephrology          (2019) 20:387 Page 6 of 6
